X4 Pharmaceuticals to Host Conference Call and Webcast to Discuss New Phase 2 Clinical Data for Mavorixafor in WHIM Syndrome to be Presented at 25ᵗʰ European Hematology Association Annual Congress

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) announced it will host a conference call on June 12, 2020, to discuss clinical efficacy and safety data from the ongoing Phase 2 trial of mavorixafor for WHIM syndrome. The data will be shared at the 25th European Hematology Association Annual Congress from June 11-14, 2020. Mavorixafor, a first-in-class treatment, is currently evaluated in a global Phase 3 trial for WHIM syndrome and in additional Phase 1b trials for other conditions. The conference call can be accessed via phone or webcast.

Positive

• The ongoing Phase 2 open-label extension trial of mavorixafor shows promising clinical efficacy and safety.
• Mavorixafor is positioned as a first-in-class therapy for WHIM syndrome and is also in Phase 3 trials.
• The upcoming presentation at the European Hematology Association Annual Congress highlights X4's commitment to research and development.

Negative

• None.

CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will host a conference call and webcast to discuss new clinical efficacy and safety data from the company’s ongoing Phase 2 open-label extension trial of its lead candidate, mavorixafor, in patients with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. The data will be presented in an e-poster (Abstract #EP852) at the 25^th European Hematology Association (EHA) Annual Congress (“Congress”), taking place virtually from June 11-14, 2020.

The X4 Pharmaceuticals conference call and webcast will take place at 8:30 am ET on June 12, 2020. The conference call can be accessed by dialing (866) 721-7655 (domestic) or (409) 216-0009 (international), followed by the conference ID: 9219476. The live webcast will be accessible on the investor relations section of the company’s website at investors.x4pharma.com. The webcast replay will be available on the website approximately two hours after the completion of the call.

The full poster will be made available on the X4 corporate website concurrent with its presentation on the Congress website at 8:30 am CET/2:30 am ET on June 12, 2020.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The Company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Cambridge, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Candice Ellis, 857-341-1043 
Director, Corporate Communications & Investor Relations 
Candice.Ellis@x4pharma.com

FAQ

What is the purpose of X4 Pharmaceuticals' clinical trial for mavorixafor?

The clinical trial aims to evaluate the efficacy and safety of mavorixafor in treating WHIM syndrome.

When will X4 Pharmaceuticals present new data on mavorixafor?

New data will be presented on June 12, 2020, at the European Hematology Association Annual Congress.

How can investors access the conference call discussing mavorixafor?

Investors can access the conference call by dialing specific numbers or via the webcast on X4 Pharmaceuticals' investor relations website.

What is mavorixafor being developed for?

Mavorixafor is being developed for rare diseases related to CXCR4 pathway dysfunction, including WHIM syndrome.

What type of therapy is mavorixafor?

Mavorixafor is a first-in-class small molecule antagonist of the CXCR4 receptor.